https://pharmexec.com

Pharmaceutical ExecutiveMaster the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.Pharmaceutical Executive NewsNewsPharma PulseMultimediaEditorial PodcastsEditorial VideosProfiles in MedicineConferencesConference CoverageConference ListingPublicationsPharmaceutical ExecutiveBrand InsightsResourcesE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapersSubscribe SpotlightPharmaceutical Executive APEX Awards Latest Executive RoundtablesTopicDE&IExecutive ProfilesSales and MarketingStrategyTechnologyNewsNewsPharma PulseMultimediaEditorial PodcastsEditorial VideosProfiles in MedicineConferencesConference CoverageConference ListingPublicationsPharmaceutical ExecutiveBrand InsightsResourcesE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapersSubscribeChoose a SpecialtySustainabilityDE&IPandemicFinanceLegalTechnologyRegulatoryGlobalPricingStrategyR&D/Clinical TrialsOpinionExecutive RoundtableSales & MarketingExecutive ProfilesLeadershipMarket AccessPatient EngagementSupply ChainIndustry TrendsAdvertisement Sales & Marketing | DE&I | Executive Profiles | Executive Roundtable | Finance | Global | Industry Trends | Leadership | Legal | Market Access | Opinion | Pandemic | Patient Engagement | Pricing | R&D/Clinical Trials | Regulatory | Strategy | Supply Chain | Sustainability | Technology View All >>DE&IExecutive ProfilesExecutive RoundtableFinanceGlobalIndustry TrendsLeadershipLegalMarket AccessOpinionPandemicPatient EngagementPricingR&D/Clinical TrialsRegulatorySales & MarketingStrategySupply ChainSustainabilityTechnologySPOTLIGHT - Pharmaceutical Executive APEX Awards | Latest Executive Roundtables Latest NewsDupixent Demonstrates Reduced Symptoms of Chronic Spontaneous Urticaria By Don Tracy, Associate EditorSeptember 12th 2024Dupixent displayed a nearly 50% reduction in itch and urticaria activity scores in patients with chronic spontaneous urticaria. FDA Approves Tremfya for Moderately to Severely Active Ulcerative Colitis By Don Tracy, Associate EditorSeptember 12th 2024Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis. Pharma Pulse 9/12/24: Enhancing Biologics Development, Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000 & moreBy Miranda SchmalfuhsSeptember 12th 2024The latest news for pharma industry insiders.How UpScriptHealth Guarantees Authenticity & Prevents Counterfeit Drugs from Entering Their Supply ChainBy Miranda SchmalfuhsSeptember 12th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, explain how their company guarantees the authenticity of the medications it dispenses, and the measures are in place to prevent counterfeit drugs from entering their supply chain.Report: Obesity Drug Market Estimated to be Worth $200 Billion by 2031By Don Tracy, Associate EditorSeptember 11th 2024A recent study by Morningstar predicts that 16 new weight-loss drugs could be on the market by 2029. Big Bets, Bold Steps Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology.Visit NowConference CoverageView AllSarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma By Don Tracy, Associate EditorJune 4th 2024Reportedly, data from the IMROZ study marks the first time an anti-CD38 monoclonal antibody combined with standard-of-care therapy has demonstrated significant improvement in progression-free survival for newly diagnosed transplant-ineligible multiple myeloma. Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection By Don Tracy, Associate EditorJune 4th 2024After three years of study, the V940 and Keytruda combination demonstrated sustained benefits in recurrence-free survival and distant metastasis-free survival in patients with high-risk melanoma following complete resection.Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung CancerBy Don Tracy, Associate EditorJune 3rd 2024Results of the ADRIATIC trial indicated that treatment with Imfinzi after standard-of-care concurrent chemoradiotherapy improves overall survival and progression-free survival in patients with limited-stage small cell lung cancer. Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient StatusBy Don Tracy, Associate EditorJune 3rd 2024Results of the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) show that 100% of participants achieved a clinical complete response when treated with Jemperli for locally advanced rectal cancer in patients with mismatch repair deficient status. Latest VideosPodcastsAll NewsAdvertisementMaking the Leap from Pharmaceuticals to Private Equity, Venture CapitalBy Michael WongSeptember 11th 2024A Harvard Business School Healthcare Alumni Association Q&A with Jeremy Goldberg of Arsenal Capital Partners.Pharma Pulse 9/11/24: 2024 Veeva R&D and Quality Summit Coverage, Oracle’s Missteps in Cloud Computing & moreBy Miranda SchmalfuhsSeptember 11th 2024The latest news for pharma industry insiders.The Importance of Obtaining Prescriptions from Legitimate SourcesBy Miranda SchmalfuhsSeptember 11th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, express the importance of obtaining prescriptions from legitimate sources and what can be done to raise awareness among consumers about the dangers.WellSync Partners With Marius to Offer Oral TRT Treatment on Digital PlatformBy Mike HollanSeptember 11th 2024Users of the platform will have access to Kyzatrex.Melissa Krebs Shares GelSana’s Vision for Innovative Wound Care Solutions By PE StaffSeptember 10th 2024In this interview, Melissa Krebs, CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer By Don Tracy, Associate EditorSeptember 10th 2024Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.TC BioPharm Announces Plans for Mpox Treatment StudiesBy Mike HollanSeptember 10th 2024The company will begin investigating the effectiveness of TCP008 for the highly infectious disease.Pharma Pulse 9/10/24: How Satellite Sites Are Outpacing Decentralized Models, Large Numbers of People Clinically Eligible for GLP-1 Drugs & moreBy Miranda SchmalfuhsSeptember 10th 2024The latest news for pharma industry insiders.The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of MedicineSeptember 10th 2024AI is a tool to make drug discovery cheaper, faster, and better — not a replacement for human ingenuity.Evernorth to Provide Stelara Biosimilar for 0$ Out-of-PocketBy Mike HollanSeptember 10th 2024This is the second biosimilar that the company is offering to its customers at this price.AdvertisementCommenting on Eli Lilly's Recent Announcement of Offering Zepbound DTCBy Miranda SchmalfuhsSeptember 10th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, comment on how Eli Lilly's recent announcement to sell Zepbound DTC will impact the counterfeit weight loss drug issue.From Endemic to POC: The Journey Pharma Marketers Need to TreadBy Thomas SheaSeptember 10th 2024The digital revolution has brought more efficient ways to reach and touch HCPs.FDA Approves Filspari for Adults with IgA NephropathyBy Don Tracy, Associate EditorSeptember 9th 2024Filspari is considered the first non-immunosuppressive treatment to significantly slow kidney function decline in adults with IgA nephropathy. Fenebrutinib Found Effective in Suppressing Relapsing Multiple Sclerosis Disease ActivityBy Don Tracy, Associate EditorSeptember 9th 2024Results of the FENopta study found that after one year of treatment, 96% of patients experienced no relapses of multiple sclerosis, with an annualized relapse rate of just 0.04.Abbott’s Continuous Glucose Monitoring Device Available in US Without a PrescriptionBy Mike HollanSeptember 9th 2024The device is part of the growing home health monitoring trend.Pharma Pulse 9/9/24: How Prepared Is Pharma for DSCSA Compliance? Companies Find a Use for VR at Work & moreBy Miranda SchmalfuhsSeptember 9th 2024The latest news for pharma industry insiders.Sun Life Expands Coverage ConnectivityBy Mike HollanSeptember 9th 2024Customers will be able to file one claim across multiple products from the company.Counterfeit Weight Loss Drugs & Potential Health RisksBy Miranda SchmalfuhsSeptember 9th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, and the potential health risks associated with them.Making Business Personal: Q&A with Cristal Downing, MerckBy Mike HollanSeptember 9th 2024The Merck executive discusses how a personal tragedy has shaped her career and approach to promoting healthy choices.Nucala Significantly Reduces Moderate to Severe Exasperations in Chronic Obstructive Pulmonary DiseaseBy Don Tracy, Associate EditorSeptember 6th 2024Results from the MATINEE trial found that Nucala led to a statistically significant and clinically meaningful reduction in moderate/severe exacerbations of chronic obstructive pulmonary disease compared to placebo over 104 weeks.AdvertisementPotential Treatment Against All COVID VariantsBy Mike HollanSeptember 6th 2024Texas Biomed announced that research shows that a certain monoclonal antibody treatment could treat all variants of COVID-19, including past, present, and future strains.FDA Approves Boruzu for Subcutaneous, Intravenous Administration for Multiple Myeloma, Mantle Cell Lymphoma By Don Tracy, Associate EditorSeptember 6th 2024Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma. Beyond the Birthrate: The Societal Costs of Maternal MortalityBy Miranda SchmalfuhsSeptember 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.Digital Protection: Q&A with Jeffrey BernsteinBy Mike HollanSeptember 6th 2024Pharma companies are facing a higher number of incredibly destructive cyber-threats than ever before.Pharma Pulse 9/6/24: Gaps and Opportunities in Qualitative Systematic Reviews, Companies Grapple With Expanding Cyber Rules & moreBy Miranda SchmalfuhsSeptember 6th 2024The latest news for pharma industry insiders.See All News >AboutAdvertiseContact EditorialEditorial Submission GuidelinesContact MJH Life SciencesDo Not Sell My Personal InformationPrivacy PolicyTerms and ConditionsContact Info2 Commerce Drive Cranbury, NJ 08512609-716-7777 © 2024 MJH Life Sciences All rights reserved.enen1729087801https://pharmexec.com

तुमची साइट संपादित करायची?

काय करत आहात?